{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T04:11:34Z","timestamp":1747368694676,"version":"3.40.5"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,15]]},"DOI":"10.7759\/cureus.84196","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:32:30Z","timestamp":1747355550000},"source":"Crossref","is-referenced-by-count":0,"title":["Missed Follow-Up and Kaposi Sarcoma Progression: The Consequences of Medication Non-adherence"],"prefix":"10.7759","author":[{"given":"Kevin","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byron","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanley","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0060-9","article-title":"Kaposi sarcoma","volume":"5","author":"Cesarman E","year":"2019","unstructured":"Cesarman E, Damania B, Krown SE, Martin J, Bower M, Whitby D. Kaposi sarcoma. Nat Rev Dis Primers. 2019, 5:9. 10.1038\/s41572-019-0060-9","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.14080","article-title":"Epidemiology of Kaposi sarcoma: review and description of the nonepidemic variant","volume":"58","author":"Vangipuram R","year":"2019","unstructured":"Vangipuram R, Tyring SK. Epidemiology of Kaposi sarcoma: review and description of the nonepidemic variant. Int J Dermatol. 2019, 58:538-42. 10.1111\/ijd.14080","journal-title":"Int J Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-21-0008","article-title":"Kaposi sarcoma incidence, burden, and prevalence in United States people with HIV, 2000-2015","volume":"30","author":"Peprah S","year":"2021","unstructured":"Peprah S, Engels EA, Horner MJ, et al.. Kaposi sarcoma incidence, burden, and prevalence in United States people with HIV, 2000-2015. Cancer Epidemiol Biomarkers Prev. 2021, 30:1627-33. 10.1158\/1055-9965.EPI-21-0008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djq134","article-title":"Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion","volume":"102","author":"Lodi S","year":"2010","unstructured":"Lodi S, Guiguet M, Costagliola D, Fisher M, de Luca A, Porter K. Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion. J Natl Cancer Inst. 2010, 102:784-92. 10.1093\/jnci\/djq134","journal-title":"J Natl Cancer Inst"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604520","article-title":"Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy","volume":"99","author":"Franceschi S","year":"2008","unstructured":"Franceschi S, Maso LD, Rickenbach M, et al.. Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. Br J Cancer. 2008, 99:800-4. 10.1038\/sj.bjc.6604520","journal-title":"Br J Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200004063421407","article-title":"Kaposi's sarcoma","volume":"342","author":"Antman K","year":"2000","unstructured":"Antman K, Chang Y. Kaposi's sarcoma. N Engl J Med. 2000, 342:1027-38. 10.1056\/NEJM200004063421407","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003860","article-title":"Explaining racial and ethnic disparities in antiretroviral therapy adherence and viral suppression among U.S. men who have sex with men","volume":"38","author":"Patel D","year":"2024","unstructured":"Patel D, Beer L, Yuan X, et al.. Explaining racial and ethnic disparities in antiretroviral therapy adherence and viral suppression among U.S. men who have sex with men. AIDS. 2024, 38:1073-80. 10.1097\/QAD.0000000000003860","journal-title":"AIDS"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0373-2","article-title":"Retention in care and medication adherence: current challenges to antiretroviral therapy success","volume":"75","author":"Holtzman CW","year":"2015","unstructured":"Holtzman CW, Brady KA, Yehia BR. Retention in care and medication adherence: current challenges to antiretroviral therapy success. Drugs. 2015, 75:445-54. 10.1007\/s40265-015-0373-2","journal-title":"Drugs"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-023-04208-8","article-title":"Antiretroviral treatment gaps and adherence among people with HIV in the U.S. Medicare program","volume":"28","author":"Li P","year":"2024","unstructured":"Li P, Prajapati G, Geng Z, et al.. Antiretroviral treatment gaps and adherence among people with HIV in the U.S. Medicare program. AIDS Behav. 2024, 28:1002-14. 10.1007\/s10461-023-04208-8","journal-title":"AIDS Behav"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(23)00051-6","article-title":"Long-acting antiretrovirals and HIV treatment adherence","volume":"10","author":"Nachega JB","year":"2023","unstructured":"Nachega JB, Scarsi KK, Gandhi M, et al.. Long-acting antiretrovirals and HIV treatment adherence. Lancet HIV. 2023, 10:e332-42. 10.1016\/S2352-3018(23)00051-6","journal-title":"Lancet HIV"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26282","article-title":"Long-acting injectable ART to advance health equity: a descriptive analysis of US clinic perspectives on barriers, needed support and programme goals for implementation from applications to the ALAI UP Project","volume":"27 Suppl 1","author":"Nguyen N","year":"2024","unstructured":"Nguyen N, Lane B, Golub SA, et al.. Long-acting injectable ART to advance health equity: a descriptive analysis of US clinic perspectives on barriers, needed support and programme goals for implementation from applications to the ALAI UP Project. J Int AIDS Soc. 2024, 27 Suppl 1:e26282. 10.1002\/jia2.26282","journal-title":"J Int AIDS Soc"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.7861\/fhj.2021-0095","article-title":"Artificial intelligence in healthcare: transforming the practice of medicine","volume":"8","author":"Bajwa J","year":"2021","unstructured":"Bajwa J, Munir U, Nori A, Williams B. Artificial intelligence in healthcare: transforming the practice of medicine. Future Healthc J. 2021, 8:e188-94. 10.7861\/fhj.2021-0095","journal-title":"Future Healthc J"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s12160-016-9830-8","article-title":"Just-in-time adaptive interventions (JITAIs) in mobile health: key components and design principles for ongoing health behavior support","volume":"52","author":"Nahum-Shani I","year":"2018","unstructured":"Nahum-Shani I, Smith SN, Spring BJ, Collins LM, Witkiewitz K, Tewari A, Murphy SA. Just-in-time adaptive interventions (JITAIs) in mobile health: key components and design principles for ongoing health behavior support. Ann Behav Med. 2018, 52:446-62. 10.1007\/s12160-016-9830-8","journal-title":"Ann Behav Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-156-11-201206050-00419","article-title":"Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel","volume":"156","author":"Thompson MA","year":"2012","unstructured":"Thompson MA, Mugavero MJ, Amico KR, et al.. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Ann Intern Med. 2012, 156:817-33, W-284, W-285, W-286, W-287, W-288, W-289, W-290, W-291, W-292, W-293, W-294. 10.7326\/0003-4819-156-11-201206050-00419","journal-title":"Ann Intern Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/369970-missed-follow-up-and-kaposi-sarcoma-progression-the-consequences-of-medication-non-adherence","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:32:31Z","timestamp":1747355551000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/369970-missed-follow-up-and-kaposi-sarcoma-progression-the-consequences-of-medication-non-adherence"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.84196","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,15]]}}}